COMPUGROUP MEDICAL SE & CO K (COP.DE) Stock Fundamental Analysis
Europe - FRA:COP - DE000A288904 - Common Stock
22.66 EUR
+0.24 (+1.07%)
Overall COP gets a fundamental rating of 3 out of 10. We evaluated COP against 10 industry peers in the Health Care Technology industry. While COP is still in line with the averages on profitability rating, there are concerns on its financial health. COP is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year COP was profitable.
COP had a positive operating cash flow in the past year.
Each year in the past 5 years COP has been profitable.
COP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
COP has a Return On Assets (1.34%) which is in line with its industry peers.
The Return On Equity of COP (4.15%) is comparable to the rest of the industry.
COP has a Return On Invested Capital of 3.53%. This is in the lower half of the industry: COP underperforms 60.00% of its industry peers.
COP had an Average Return On Invested Capital over the past 3 years of 4.07%. This is below the industry average of 9.03%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROIC | 3.53% |
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
1.3 Margins
COP has a Profit Margin (2.34%) which is in line with its industry peers.
COP's Profit Margin has declined in the last couple of years.
COP's Operating Margin of 8.13% is in line compared to the rest of the industry. COP outperforms 60.00% of its industry peers.
In the last couple of years the Operating Margin of COP has declined.
With a decent Gross Margin value of 83.85%, COP is doing good in the industry, outperforming 70.00% of the companies in the same industry.
In the last couple of years the Gross Margin of COP has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% |
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), COP is destroying value.
Compared to 1 year ago, COP has less shares outstanding
Compared to 5 years ago, COP has more shares outstanding
COP has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.79, we must say that COP is in the distress zone and has some risk of bankruptcy.
COP has a Altman-Z score (1.79) which is in line with its industry peers.
The Debt to FCF ratio of COP is 9.74, which is on the high side as it means it would take COP, 9.74 years of fcf income to pay off all of its debts.
COP has a Debt to FCF ratio (9.74) which is in line with its industry peers.
A Debt/Equity ratio of 1.22 is on the high side and indicates that COP has dependencies on debt financing.
COP has a Debt to Equity ratio of 1.22. This is amonst the worse of the industry: COP underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Altman-Z | 1.79 |
ROIC/WACC0.67
WACC5.27%
2.3 Liquidity
COP has a Current Ratio of 1.12. This is a normal value and indicates that COP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.12, COP is doing worse than 60.00% of the companies in the same industry.
A Quick Ratio of 1.09 indicates that COP should not have too much problems paying its short term obligations.
COP has a worse Quick ratio (1.09) than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
The earnings per share for COP have decreased strongly by -45.71% in the last year.
Measured over the past years, COP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.58% on average per year.
Looking at the last year, COP shows a decrease in Revenue. The Revenue has decreased by -2.19% in the last year.
The Revenue has been growing by 9.12% on average over the past years. This is quite good.
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%
3.2 Future
The Earnings Per Share is expected to grow by 9.19% on average over the next years. This is quite good.
Based on estimates for the next years, COP will show a small growth in Revenue. The Revenue will grow by 0.36% on average per year.
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 43.58 indicates a quite expensive valuation of COP.
The rest of the industry has a similar Price/Earnings ratio as COP.
When comparing the Price/Earnings ratio of COP to the average of the S&P500 Index (26.76), we can say COP is valued expensively.
With a Price/Forward Earnings ratio of 12.88, COP is valued correctly.
70.00% of the companies in the same industry are more expensive than COP, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.63. COP is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 |
4.2 Price Multiples
70.00% of the companies in the same industry are more expensive than COP, based on the Enterprise Value to EBITDA ratio.
COP's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. COP is cheaper than 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.34 | ||
| EV/EBITDA | 9.24 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)31.03
PEG (5Y)N/A
EPS Next 2Y4.91%
EPS Next 3Y9.19%
5. Dividend
5.1 Amount
COP has a yearly dividend return of 0.22%, which is pretty low.
Compared to an average industry Dividend Yield of 3.36, COP has a dividend in line with its industry peers.
With a Dividend Yield of 0.22, COP pays less dividend than the S&P500 average, which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
5.2 History
On average, the dividend of COP grows each year by 14.75%, which is quite nice.
Dividend Growth(5Y)14.75%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
191.63% of the earnings are spent on dividend by COP. This is not a sustainable payout ratio.
COP's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP191.63%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
FRA:COP (6/24/2025, 7:00:00 PM)
22.66
+0.24 (+1.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners13.38%
Inst Owner ChangeN/A
Ins Owners53.51%
Ins Owner ChangeN/A
Market Cap1.22B
Revenue(TTM)1.16B
Net Income(TTM)27.00M
Analysts56.67
Price Target21.32 (-5.91%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.22% |
Yearly Dividend1
Dividend Growth(5Y)14.75%
DP191.63%
Div Incr Years2
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.58 | ||
| Fwd PE | 12.88 | ||
| P/S | 1.05 | ||
| P/FCF | 14.34 | ||
| P/OCF | 8.46 | ||
| P/B | 1.87 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.24 |
EPS(TTM)0.52
EY2.29%
EPS(NY)1.76
Fwd EY7.76%
FCF(TTM)1.58
FCFY6.97%
OCF(TTM)2.68
OCFY11.82%
SpS21.51
BVpS12.12
TBVpS-12.86
PEG (NY)31.03
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.34% | ||
| ROE | 4.15% | ||
| ROCE | 5.85% | ||
| ROIC | 3.53% | ||
| ROICexc | 3.83% | ||
| ROICexgc | 41.76% | ||
| OM | 8.13% | ||
| PM (TTM) | 2.34% | ||
| GM | 83.85% | ||
| FCFM | 7.35% |
ROA(3y)2.65%
ROA(5y)3.3%
ROE(3y)7.71%
ROE(5y)9.17%
ROIC(3y)4.07%
ROIC(5y)4.45%
ROICexc(3y)4.31%
ROICexc(5y)4.74%
ROICexgc(3y)36.56%
ROICexgc(5y)51.39%
ROCE(3y)6.74%
ROCE(5y)7.38%
ROICexgc growth 3Y-23.91%
ROICexgc growth 5Y-9.04%
ROICexc growth 3Y-4.3%
ROICexc growth 5Y-14.26%
OM growth 3Y-2.61%
OM growth 5Y-10.29%
PM growth 3Y-23.61%
PM growth 5Y-19.42%
GM growth 3Y32.01%
GM growth 5Y16.44%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.22 | ||
| Debt/FCF | 9.74 | ||
| Debt/EBITDA | 3.86 | ||
| Cap/Depr | 52.61% | ||
| Cap/Sales | 5.11% | ||
| Interest Coverage | 2.54 | ||
| Cash Conversion | 69.81% | ||
| Profit Quality | 314.42% | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z | 1.79 |
F-Score6
WACC5.27%
ROIC/WACC0.67
Cap/Depr(3y)60.99%
Cap/Depr(5y)64.22%
Cap/Sales(3y)5.98%
Cap/Sales(5y)6.31%
Profit Quality(3y)175.79%
Profit Quality(5y)158.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.71%
EPS 3Y-20.77%
EPS 5Y-13.58%
EPS Q2Q%-40%
EPS Next Y1.4%
EPS Next 2Y4.91%
EPS Next 3Y9.19%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.19%
Revenue growth 3Y4.02%
Revenue growth 5Y9.12%
Sales Q2Q%0.54%
Revenue Next Year2.47%
Revenue Next 2Y2.65%
Revenue Next 3Y2.49%
Revenue Next 5Y0.36%
EBIT growth 1Y-18.88%
EBIT growth 3Y1.31%
EBIT growth 5Y-2.11%
EBIT Next Year77.58%
EBIT Next 3Y24.98%
EBIT Next 5Y17.79%
FCF growth 1Y3.01%
FCF growth 3Y-11.08%
FCF growth 5Y-0.24%
OCF growth 1Y-8.49%
OCF growth 3Y-7.96%
OCF growth 5Y3.13%
COMPUGROUP MEDICAL SE & CO K / COP.DE FAQ
What is the ChartMill fundamental rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to COP.DE.
What is the valuation status of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to COMPUGROUP MEDICAL SE & CO K (COP.DE). This can be considered as Overvalued.
How profitable is COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
COMPUGROUP MEDICAL SE & CO K (COP.DE) has a profitability rating of 4 / 10.
What is the valuation of COMPUGROUP MEDICAL SE & CO K based on its PE and PB ratios?
The Price/Earnings (PE) ratio for COMPUGROUP MEDICAL SE & CO K (COP.DE) is 43.58 and the Price/Book (PB) ratio is 1.87.
What is the financial health of COMPUGROUP MEDICAL SE & CO K (COP.DE) stock?
The financial health rating of COMPUGROUP MEDICAL SE & CO K (COP.DE) is 2 / 10.